Cellectis (CLLS) Cash from Investing Activities Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 116.52% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.24% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -22.09% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 30.54% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -264.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -264.31% |
| Dec 31, 2025 | 219.96% |
| Sep 30, 2025 | -143.61% |
| Jun 30, 2025 | -262.47% |
| Mar 31, 2025 | 101.29% |
| Dec 31, 2024 | -14.22% |
| Sep 30, 2024 | 122.98% |
| Jun 30, 2024 | -135.42% |
| Mar 31, 2024 | -105.52% |
| Dec 31, 2023 | -49.62% |
| Sep 30, 2023 | -28.70% |
| Jun 30, 2023 | 30.76% |
| Mar 31, 2023 | 26.05% |
| Dec 31, 2022 | 33.95% |
| Sep 30, 2022 | 79.03% |
| Jun 30, 2022 | 28.97% |
| Mar 31, 2022 | 46.40% |
| Dec 31, 2021 | -75.83% |
| Sep 30, 2021 | -28.74% |
| Jun 30, 2021 | -21.41% |
| Mar 31, 2021 | 36.84% |
| Dec 31, 2020 | 178.54% |
| Sep 30, 2020 | -28.11% |
| Jun 30, 2020 | 25.93% |
| Mar 31, 2020 | -158.37% |
| Dec 31, 2019 | -27.10% |
| Sep 30, 2019 | -72.07% |
| Jun 30, 2019 | 16.29% |
| Mar 31, 2019 | 64.84% |
| Dec 31, 2018 | -27.99% |
| Sep 30, 2018 | 658.72% |
| Jun 30, 2018 | 98.35% |
| Mar 31, 2018 | 45.20% |